Kuros Financial Statements From 2010 to 2024
| KURN Stock | CHF 6.67 0.14 2.14% |
Check Kuros Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kuros main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Kuros financial statements analysis is a perfect complement when working with Kuros Biosciences Valuation or Volatility modules.
Kuros |
Kuros Biosciences AG Company Return On Asset Analysis
Kuros Biosciences' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kuros Biosciences Return On Asset | -0.0667 |
Most of Kuros Biosciences' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kuros Biosciences AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kuros Biosciences AG has a Return On Asset of -0.0667. This is 99.24% lower than that of the Healthcare sector and 99.72% lower than that of the Biotechnology industry. The return on asset for all Switzerland stocks is 52.36% lower than that of the firm.
Kuros Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kuros Biosciences's current stock value. Our valuation model uses many indicators to compare Kuros Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kuros Biosciences competition to find correlations between indicators driving Kuros Biosciences's intrinsic value. More Info.Kuros Biosciences AG is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kuros Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kuros Biosciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kuros Biosciences' earnings, one of the primary drivers of an investment's value.About Kuros Biosciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Kuros Biosciences income statement, its balance sheet, and the statement of cash flows. Kuros Biosciences investors use historical funamental indicators, such as Kuros Biosciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Kuros Biosciences investors may use each financial statement separately, they are all related. The changes in Kuros Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kuros Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kuros Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kuros Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland. Kuros N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 35 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kuros Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kuros Biosciences' short interest history, or implied volatility extrapolated from Kuros Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Kuros Biosciences Correlation against competitors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Kuros Stock analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |